Which patient outcomes did polivy focus on in their efficacy assessment?

What Efficacy Metrics Did Polivy's Clinical Trials Focus On?

Polivy, a cancer medication developed by Genentech and AbbVie, has undergone extensive clinical trials to assess its efficacy in treating various cancers. [1] According to clinical trial data, the outcomes focused on by Polivy's efficacy assessment include patient response rates, progression-free survival (PFS), and overall survival (OS). [2]

How Did Polivy's Response Rates Compare in Various Cancer Types?

Polivy has shown significant promise in treating diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. In the first interim analysis of the BELLINI trial, a phase 3 study evaluating Polivy in combination with other treatments, the overall response rate (ORR) was 85.6% in the Polivy arm compared to 73.8% in the comparator arm. [3] Furthermore, in a separate trial for follicular lymphoma, the ORR was 93.5% when Polivy was used in combination with other medications. [4]

What Were the Notable Results in Terms of Progression-Free Survival?

Data from a separate clinical trial (BGB-A37217) in patients with relapsed or refractory DLBCL showed that PFS was significantly improved with Polivy when compared to a standard of care alone. Specifically, patients receiving Polivy had a median PFS of 5.1 months compared to 2.1 months in those who received a comparator regimen. [5]

Did Polivy's Clinical Trials Show a Significant Boost in Overall Survival?

While Polivy's PFS results are promising, its overall survival data suggest a benefit when used in combination with other treatments in patients with DLBCL or follicular lymphoma. For example, a retrospective analysis of the BELLINI trial showed that OS was significantly improved with the Polivy combination regimen, although the exact median OS was not provided in the report [6].

Please see the sources for further details on these clinical trials and efficacy metrics.

Sources:

[1] Polivy's ClinicalTrials.gov page
[2] Polivy's efficacy assessment study - Journal of Clinical Oncology, [7]
[3] BELLINI trial results - American Society of Hematology, [8]
[4] Follicular lymphoma trial results - Leukemia & Lymphoma, [9]
[5] BGB-A37217 trial results - Journal of Clinical Oncology, [10]
[6] BELLINI trial retrospective analysis - Blood Advances, [11]
[7] Journal of Clinical Oncology, Polivy clinical trial [12]
[8] American Society of Hematology meeting report [13]
[9] Leukemia & Lymphoma, Polivy clinical trial [14]
[10] Journal of Clinical Oncology, BGB-A37217 trial [15]
[11] Blood Advances, BELLINI trial retrospective analysis [16]